AKTX
No price yet
Announcements
Nothing here yet
Daily updates
- Akari Therapeutics expanded its IP portfolio with a PCT application covering its PH1 RNA-splicing ADC payload and its ability to regulate oncogenic pathways including angiogenesis, apoptosis, and androgen receptor signaling. The filing strengthens international patent protection for its Thailanstatin-derived ADC platform as PH1 advances across oncology indications.Oct 4, 2026
- AKTX-101 showed tumor suppression in resistant urothelial cancer modelsAug 20, 2026
- AKTX-101 showed tumor suppression in preclinical urothelial cancer modelsAug 19, 2026
FDA designations
Nothing here yet
News
- Akari Therapeutics expands its intellectual property portfolio with a PCT filing for an ADC payload targeting RNA splicing in cancerOct 1, 2026
- Akari Therapeutics reported compelling urothelial cancer data supporting the differentiated ADC strategy for AKTX-101Aug 19, 2026
- Akari reports breakthrough preclinical data showing synergistic activity of AKTX-101 with KRAS inhibitors in pancreatic cancerMay 23, 2026
- Akari Therapeutics secures key European patent for RNA splicing modulator ADC payloadMay 12, 2026
- Akari Therapeutics received Australian patent approval, expanding global protection for its proprietary PH1 RNA splicing modulator ADC payloadApr 27, 2026